Kimberly Orleck
Medical · Atlanta, GANPI 1952632580
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $506,115 of the $727,327 with a category attached, or 69.6%. 34 manufacturers reported payments, led by AbbVie at 41.9% of the total. Among medical clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,508 payments — averaging $482.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$305K
- Johnson & Johnson$185K
- Lilly USA, LLC$47K
- Pfizer$42K
- Janssen Scientific Affairs, LLC$40K
- Phathom Pharmaceuticals, Inc.$22K
- plus $87K from 28 others
What the payments were for
- Consulting fees$102,55114%
- Speaking & faculty fees$506,11570%
- Travel & lodging$94,96613%
- Food & beverage$23,6043%
- Education$920%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 622 | $304,917 |
| Johnson & Johnson | 259 | $184,875 |
| Lilly USA, LLC | 110 | $47,175 |
| Pfizer | 55 | $41,853 |
| Janssen Scientific Affairs, LLC | 49 | $39,643 |
| Phathom Pharmaceuticals, Inc. | 40 | $21,863 |
| Ironwood Pharmaceuticals, Inc | 44 | $18,600 |
| E.r. Squibb & Sons, L.L.C. | 38 | $17,282 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 97 | $16,744 |
| Ardelyx, Inc. | 64 | $15,386 |
| Eli Lilly | 8 | $7,038 |
| Takeda Pharmaceuticals U.S.A., Inc. | 41 | $6,592 |
| Bristol Myers Squibb | 23 | $1,756 |
| Sanofi | 5 | $1,723 |
| Regeneron Healthcare Solutions, Inc. | 6 | $689 |
| Exact Sciences | 2 | $228 |
| Merck | 10 | $186 |
| Nestle Healthcare Nutrition Inc. | 8 | $138 |
| Medtronic | 1 | $89 |
| Vivus LLC | 6 | $86 |
| QOL Medical, LLC | 3 | $75 |
| Sebela Pharmaceuticals Inc. | 1 | $70 |
| Aimmune Therapeutics, Inc. | 3 | $64 |
| Daiichi Sankyo Inc. | 2 | $37 |
| Ferring Pharmaceuticals Inc. | 2 | $32 |
| Boehringer Ingelheim | 1 | $25 |
| Boston Scientific | 1 | $24 |
| Braintree Laboratories, Inc. | 1 | $24 |
| Amgen | 1 | $23 |
| Organon | 1 | $22 |
| Celltrion USA Inc. | 1 | $20 |
| Fresenius Kabi USA, LLC | 1 | $18 |
| Ipsen Biopharmaceuticals, Inc | 1 | $18 |
| Redhill Biopharma Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$727,327 in reported general payments places this provider in the 95th percentile of 950 medical providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 17 | $497,497 |
| Humira(Cf) PenAdalimumab | 18 | $193,982 |
| CreonLipase/Protease/Amylase | 30 | $138,678 |
| RinvoqUpadacitinib | 11 | $95,722 |
| XifaxanRifaximin | 24 | $64,515 |
| LinzessLinaclotide | 39 | $56,894 |
| IbsrelaTenapanor Hcl | 17 | $40,687 |
| VoqueznaVonoprazan Fumarate | 40 | $33,480 |
| TrulancePlecanatide | 23 | $32,905 |
| MotegrityPrucalopride Succinate | 26 | $28,631 |
| Dexlansoprazole DrDexlansoprazole | 45 | $18,763 |
| Mesalamine | 33 | $16,643 |
| Colesevelam Hcl | 14 | $5,786 |
| Lubiprostone | 32 | $4,102 |
| Omeprazole | 211 | $2,344 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $184,875 | $497,49717 claims |
| AbbVieCreon, Rinvoq, Linzess | $304,917 | $291,29480 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $16,744 | $97,42047 claims |
| Ardelyx, Inc.Ibsrela | $15,386 | $40,68717 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $21,863 | $33,48040 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $6,592 | $28,63126 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 950 medical providers in Georgia.
Other medical in Atlanta
- Danna Dennis-CalderAtlanta$87K
- Ferrina ShethAtlanta$49K
- Adriana RuizAtlanta$39K
- Punam PunjaAtlanta$31K
- Adrienne AndersonAtlanta$25K
- Jeremiah RobinsonAtlanta$23K
- Steven SchmittAtlanta$15K
- Taylor WeintraubAtlanta$15K
- Margaret SellersAtlanta$11K
- Katherine QuinleyAtlanta$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.